- Home
- ESGL vs CRDL Comparison
ESGL vs CRDL Comparison
Compare ESGL & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- CRDL
- Stock Information
- Founded
- ESGL 1999
- CRDL 2017
- Country
- ESGL Singapore
- CRDL Canada
- Employees
- ESGL N/A
- CRDL N/A
- Industry
- ESGL
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESGL
- CRDL Health Care
- Exchange
- ESGL Nasdaq
- CRDL Nasdaq
- Market Cap
- ESGL 114.6M
- CRDL 126.5M
- IPO Year
- ESGL N/A
- CRDL N/A
- Fundamental
- Price
- ESGL $2.84
- CRDL $1.10
- Analyst Decision
- ESGL
- CRDL Strong Buy
- Analyst Count
- ESGL 0
- CRDL 2
- Target Price
- ESGL N/A
- CRDL $9.00
- AVG Volume (30 Days)
- ESGL 10.9K
- CRDL 1.4M
- Earning Date
- ESGL 09-23-2025
- CRDL 08-14-2025
- Dividend Yield
- ESGL N/A
- CRDL N/A
- EPS Growth
- ESGL N/A
- CRDL N/A
- EPS
- ESGL N/A
- CRDL N/A
- Revenue
- ESGL $6,099,784.00
- CRDL N/A
- Revenue This Year
- ESGL N/A
- CRDL N/A
- Revenue Next Year
- ESGL N/A
- CRDL N/A
- P/E Ratio
- ESGL N/A
- CRDL N/A
- Revenue Growth
- ESGL N/A
- CRDL N/A
- 52 Week Low
- ESGL $0.90
- CRDL $0.77
- 52 Week High
- ESGL $3.87
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- ESGL 54.15
- CRDL 42.61
- Support Level
- ESGL $2.49
- CRDL $1.12
- Resistance Level
- ESGL $2.70
- CRDL $1.42
- Average True Range (ATR)
- ESGL 0.15
- CRDL 0.09
- MACD
- ESGL 0.01
- CRDL -0.00
- Stochastic Oscillator
- ESGL 100.00
- CRDL 11.11
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.